StockData

Integra LifeSciences vs LivaNova

IART and LIVN side by side, both in surgical, medical, and dental instruments and supplies. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How IART and LIVN compare

LivaNova is the larger company, worth 4.8 times as much as Integra LifeSciences ($5.1B against $1.1B).

On earnings, LivaNova is cheaper: it trades at 27.1× trailing earnings, against 79.7× for Integra LifeSciences.

LivaNova grew revenue faster over the last twelve months (12.4% versus 0.84% for Integra LifeSciences).

LivaNova keeps more of each dollar of sales as profit, with a net margin of 12.8% compared with 0.79% at Integra LifeSciences.

LivaNova scores higher on the StockData Score (13 against 9 for Integra LifeSciences), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricIARTLIVN
Size and price
Market cap$1.1B$5.1B
Share price$13.55$91.92
Change, 1 year15.3%66.0%
Change, 5 years−79.1%10.3%
Beta (5Y)1.910.83
Employees3,7003,300
StockData Score
Total score913 (better)
Valuation score3 (better)0
Growth score24 (better)
Performance score34 (better)
Health score15 (better)
Dividend score00
Valuation
P/E79.7×27.1× (better)
P/S0.6× (better)3.4×
P/B1.0× (better)3.8×
EV/EBITDA10.2× (better)25.8×
P/FCF12.3× (better)34.1×
FCF yield8.1% (better)2.9%
Fair value$14.78$69.65
Margin of safety8.3% (better)−32.0%
Growth
Revenue growth (TTM)0.84%12.4% (better)
Revenue growth, 5Y average3.6%8.2% (better)
Profitability
Gross margin52.4%68.1% (better)
Operating margin4.4%12.7% (better)
Net margin0.79%12.8% (better)
FCF margin5.2%10.1% (better)
Return on equity1.2%15.4% (better)
Return on invested capital5.6%18.2% (better)
Financial health
Debt / equity–0.22
Net debt / EBITDA–−1.19
Interest coverage0.8×5.0× (better)
Current ratio3.62 (better)1.45
Altman Z-score1.272.71 (better)
Piotroski F-score55
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions94.4%108%
Held by insiders3.4%0.48%
Insider net buying, 12 months$0 (better)−$1.3M
Short interest, % of float10.5%11.6%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.